Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethaselen (BBSKE), a selective thioredoxin reductase (TrxR) inhibitor, is orally active with IC50s of 0.5 and 0.35 μM for wild-type human TrxR1 and rat TrxR1, respectively. Ethaselen specifically binds to the unique selenocysteine-cysteine redox pair located in the C-terminal active site of mammalian TrxR1. As an organoselenium compound, it demonstrates potent antitumor activity against non-small cell lung cancer (NSCLC) by targeting TrxR.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,600 | 现货 | ||
5 mg | ¥ 2,710 | 现货 | ||
25 mg | ¥ 9,540 | 现货 | ||
50 mg | ¥ 12,400 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,250 | 现货 |
产品描述 | Ethaselen (BBSKE), a selective thioredoxin reductase (TrxR) inhibitor, is orally active with IC50s of 0.5 and 0.35 μM for wild-type human TrxR1 and rat TrxR1, respectively. Ethaselen specifically binds to the unique selenocysteine-cysteine redox pair located in the C-terminal active site of mammalian TrxR1. As an organoselenium compound, it demonstrates potent antitumor activity against non-small cell lung cancer (NSCLC) by targeting TrxR. |
体外活性 | Ethaselen (2.5-10 μM; 12, 24 hours) suppresses A549 cell viability in a both concentration- and time-dependent manner. H1666, which has considerably lower TrxR1 expression level, is less susceptible to 24 h treatment with Ethaselen[1]. Ethaselen inhibits the intracellular TrxR1 activity in a concentration- and time-dependent manner, with IC 50 values of 4.2 and 2 μM for 12- and 24-h treatments, respectively[1]. Ethaselen (2.5-10 μM; 12, 24 hours) has no effect on the protein amounts of TrxR1 and Trx. The mRNA level of TrxR1 does not show significant alteration in Ethaselen-treated A549 cells[1]. Ethaselen (2.5-50 μM; 1-24 hours) causes intracellular Trx oxidation in A549 cells[1]. Ethaselen (5-10 μM; 12, 24 hours) causes a clear concentration-dependent increase in ROS levels in A549 cells[1]. The inhibition constants for Ethaselen binding to free enzyme (K i ) and the enzyme-substrate complex (K is ) were determined to be 0.022 and 0.087 μM, respectively. Ethaselen also inhibits mammalian TrxR1 in a time-dependent manner possibly by forming a covalent Se-S bond with Cys497 of Trx[1]. Cell Viability Assay[1]Cell Line: A549 cell Concentration: 2.5, 5, 7.5, 10 μM Incubation Time: 12, 24 hours Result: Suppressed A549 cell viability in a both concentration- and time-dependent manner. |
体内活性 | Ethaselen (BBSKE; 36-108 mg/kg/day; PO; for 10 days) shows increased inhibition of tumor growth in a dose-independent manner[2]. Animal Model: Five-week-old female BALB/c nude mice with A549 cell[2]Dosage: 36, 72, 108 mg/kg Administration: PO; daily; for 10 days Result: Showed increased inhibition of tumor growth, and the inhibition levels increased with the dose. The TrxR activity levels of the high dose group (108 mg/kg) decreased more than the middle dose group (72 mg/kg) and low dose group (36 mg/kg). |
别名 | BBSKE |
分子量 | 422.226 |
分子式 | C16H12N2O2Se2 |
CAS No. | 217798-39-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ethaselen 217798-39-5 BBSKE Inhibitor inhibitor inhibit